Let us introduce you to ROBBYCOL by Liqbiopsens. A novel diagnostic platform for the early and fast detection of ctDNA and their mutations associated with colorectal cancer through blood samples.
We launched our new Facebook page have a look on it! Some news are comming!
A very interesting article published on the Impact magazine explaining the novelties and power of the Liqbiopsens project results.
A new article has been published with inputs from the results of our consortium work. A very interesting approach for the integration of a microfluidic platform and a multi-channel quartz crystal microbalance array on a printed circuit board (PCB) using a dry adhesive bonding method.
Project members on our annual meeting.
Commenced in January 2016, the Liqbiopsens Consortium members held a very successful penultimate review meeting on July 26thin Granada, Spain. The consortium, supported financially by the EU, has together researchers and biotechnology companies in Spain, Belgium, Greece and the UK. The sole purpose of the Liqbiopsens project is to develop a novel detection platform and test for improved diagnosis of colon cancer, replacing traditional tissue pathology by a ‘liquid biopsy’ taken from a blood sample.
Project progress, expert reviewer advice and agreement on the next six months work plans were hammered out between the consortium member, EU project manager and EU appointed experts. Individual consortium members leading the various project Work Packages gave presentations.
The consortium brings together researchers and biotechnology companies, with the sole objective to develop a novel platform and improved test for colon cancer, using a novel ‘liquid biopsy’ taken from a blood sample. To be able to directly detect biomarkers from blood samples requires a sophisticated, ultrasensitive detection platform based on the use of sound waves, able to accurately detect and discriminate patients with colon cancer, especially at an early stage.
The project aims to be completed by the end of 2018 with a working prototype that has demonstrated a highly reliable detection of colon cancer from patient liquid biopsies.
National media shows the progress of Liqbiopsens project advances.
Electra Gizeli member of the Liqbiopsens Consortium and usging part of its results wrote the 9th Chapter of this book published in January 2018.
Dr. Souglakos, renowned oncologist, identified a significant advantage for liquid biopsies: monitoring patient progress following clinical intervention LIQUID BIOPSY, KEY FOR IMPROVING CANCER TREATMENT AND CUTTING DOWN DRUG EXPENDITURE LiqBiopSens... read the whole news
Very good news for our project, regarding the bet done by this consortium on liquid biopsy. The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can... read the whole news
A new article published explaining the modification made for using an acoustic wave sensor for Bio-Sensing Applications.
See also: https://www.mdpi.com/1424-8220/17/9/2057
Hugh Ilyine, CEO of DestiNA Genomics present the Liqbiopsens project on the FIRST INTERNATIONAL SYMPOSIUM on LIQUID BIOPSIES 2016, on a satelyte symposium called Liqbiopsens- "an EU Horizon 2020 consortium, combining novel technologies... read the whole news
The Liqbiposens consortium carried out his periodic review meeting in Crete (Grece) past 7th and 8th July. The Different work packages leaders present the status of their packages and establish the next actions to be taken. A very good feedback once finish... read the whole news
That was one of the key questions in the last “Sensing for Smart Anything Everywhere: Materials, Technologies, Applications” workshop, held at Otranto, Italy, last June. It was an event focused on the technological orientation and future challenges... read the whole news